Myeloproliferative cancer treatment drug TG-101348
Being developed by Sanofi Ph chromosome-negative myeloproliferative neoplasms (MPNs) therapeutic TG-101348 (ie SAR-302503) as an orally active small molecule with a protein tyrosine kinase JAK2 (Janus kinase 2) inhibitor, has been in the U.S. orphan drug status. MPNs including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) and other rare myeloproliferative disease caused by abnormal clonal expansion of hematopoietic progenitor cells due.
Myeloproliferative cancer treatment drug TG-101348
ReplyDeleteBeing developed by Sanofi Ph chromosome-negative myeloproliferative neoplasms (MPNs) therapeutic TG-101348 (ie SAR-302503) as an orally active small molecule with a protein tyrosine kinase JAK2 (Janus kinase 2) inhibitor, has been in the U.S. orphan drug status. MPNs including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) and other rare myeloproliferative disease caused by abnormal clonal expansion of hematopoietic progenitor cells due.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Flavopiridol
Flavopiridol hydrochloride
SNS-032
AZD-5438
R547
PHA-848125
Dinaciclib
PHA-793887
CGP60474
CDK inhibitor II